- Home
- INO vs NSPR Comparison
INO vs NSPR Comparison
Compare INO & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- NSPR
- Stock Information
- Founded
- INO 1979
- NSPR 2005
- Country
- INO United States
- NSPR Israel
- Employees
- INO N/A
- NSPR N/A
- Industry
- INO Medical/Dental Instruments
- NSPR Medical/Dental Instruments
- Sector
- INO Health Care
- NSPR Health Care
- Exchange
- INO Nasdaq
- NSPR Nasdaq
- Market Cap
- INO 75.4M
- NSPR 63.0M
- IPO Year
- INO 1998
- NSPR N/A
- Fundamental
- Price
- INO $2.24
- NSPR $3.19
- Analyst Decision
- INO Buy
- NSPR Strong Buy
- Analyst Count
- INO 6
- NSPR 2
- Target Price
- INO $17.00
- NSPR $4.75
- AVG Volume (30 Days)
- INO 739.9K
- NSPR 50.3K
- Earning Date
- INO 03-05-2025
- NSPR 03-05-2025
- Dividend Yield
- INO N/A
- NSPR N/A
- EPS Growth
- INO N/A
- NSPR N/A
- EPS
- INO N/A
- NSPR N/A
- Revenue
- INO $203,413.00
- NSPR $6,821,000.00
- Revenue This Year
- INO N/A
- NSPR $13.36
- Revenue Next Year
- INO $1,970.14
- NSPR $49.64
- P/E Ratio
- INO N/A
- NSPR N/A
- Revenue Growth
- INO N/A
- NSPR 24.70
- 52 Week Low
- INO $1.74
- NSPR $1.81
- 52 Week High
- INO $14.75
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- INO 54.46
- NSPR 63.51
- Support Level
- INO $1.82
- NSPR $2.60
- Resistance Level
- INO $2.31
- NSPR $3.11
- Average True Range (ATR)
- INO 0.14
- NSPR 0.28
- MACD
- INO 0.05
- NSPR 0.05
- Stochastic Oscillator
- INO 83.17
- NSPR 87.15
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.